Highlights

  • Immutep (ASX:IMM) is concentrating its development strategy around eftilagimod alfa (efti).
  • The company discontinued its Phase 3 TACTI-004 lung cancer trial after interim analysis results.
  • Efti is being redirected towards selected cancer indications including head and neck cancer and soft tissue sarcoma.
  • Manufacturing comparability, regulatory progress and future clinical studies remain key areas to monitor.

Immutep Limited (ASX:IMM) is a biotechnology company focused on immune checkpoint technology, particularly the LAG-3 pathway. The company’s main asset, eftilagimod alfa or efti, is designed to activate antigen-presenting cells through the MHC Class II pathway to support immune responses against tumours.

Following the outcome of its Phase 3 TACTI-004 lung cancer programme, Immutep reviewed its development strategy and shifted attention towards selected indications where it believes further evaluation of efti may be appropriate.

Understanding the TACTI-004 Outcome

TACTI-004 evaluated efti in first-line non-small cell lung cancer. The company discontinued the trial after a futility analysis indicated that the study was unlikely to demonstrate the intended outcome.

Immutep reported interim data showing a response rate of 42.9% in the efti treatment group compared with 55.1% in the control group. The company later identified Manufacturing differences between efti used in earlier studies and the material used in TACTI-004 as an area requiring further investigation.

The company has initiated a new manufacturing run using earlier production conditions to assess comparability with previously studied material.

New Focus Areas for Efti

Rather than discontinuing efti development, Immutep has redirected attention towards additional indications. These include head and neck squamous cell carcinoma in patients with low PD-L1 expression and soft tissue sarcoma in the neoadjuvant setting.

The company has reported regulatory designations associated with these programmes and is working towards future clinical studies, subject to regulatory requirements and completion of manufacturing activities.

Financial Position and Development Considerations

Immutep reported cash, cash equivalents and term deposits of approximately A$68.9 million at 30 June 2026. The company also implemented cost reduction measures following the TACTI-004 outcome.

Although the company has financial resources to support operations, future clinical development requires continued Investment in manufacturing, regulatory activities and trials. The timing of new studies and future data releases will influence the next stage of development.

Key Insights

Immutep’s current strategy is centred on determining whether efti can demonstrate clinical value in more targeted settings after the lung cancer programme did not meet expectations. The company’s progress will depend on manufacturing validation, regulatory milestones and evidence generated from future clinical studies.